Separase InhibitoreSepin-1 has shown great promise as a developmental chemotherapeutic agent to treat Separaseoverexpressing tumors, however, very little is known about its toxicity profile. Here we present the data set of organ weights, hematology, and clinical chemistry parameters in Sepin-1-treated Sprague-Dawley rats. The data set was generated from two study groupseMain Study and Recovery Study, with in-life duration of 29 and 57 days, respectively. Rats in both groups were dosed with 0, 5, 10 and 20 mg/kg of Sepin-1 once daily for 28 consecutive days. Blood samples from rats in Main Study were collected and their organs were weighed on day 29. The animals in Recovery Study were on a dose-off period of 28 days after dosed with Sepin-1 for 28 days, and their blood samples and organ weight data were collected on day 57. Body weights of rats in both Main and Recovery Study were collected twice a week. Hematology parameters of whole blood samples, such as hemoglobin concentration, counts of platelet and blood cells etc., were determined. Clinical chemistry parameters of serum, such as concentrations of albumin, glucose, cholesterol, triglyceride, alanine/aspartate aminotransferase, ect., were measured. Further analysis may yield useful information regarding the toxicity of Sepin-1 in Sprague-Dawley Rats. Data presented here are related to a research article entitled "Toxicity
Data
The dataset in this article contains body and organ weights, hematology, and clinical chemistry parameters in Sprague-Dawley rats that were dosed with Separase inhibitoreSepin-1 in Good Laboratory Practice (GLP) setting. The animals randomly assigned in two study groupseMain Study and Recovery Study. Both study groups were dosed with Sepin-1 once daily for 28 consecutive days. Animals in Main Study group were terminated on day 29. Animals in Recovery Study were allowed to recover for 28 days and terminated on day 57. On the termination day organ weights were collected and blood samples were obtained for hematology and clinical chemistry analyses. Tables 1 and 2 show group mean body weights data in Main Study and Recovery Study, respectively, which were collected twice a week. Tables 3e5 are group mean organ weights, organ weights relative to brain weight, and organ weights relative to body weight in rats of Main Study, respectively. Tables 6e8 describe group mean organ weights, organ weights relative to brain weight, and organ weights relative to body weight in rats of Recovery Study, respectively. Tables 9 and 10 show group mean hematology parameters in male and female rats of Main Study, respectively. Tables 11 and 12 display group mean hematology parameters in male and female rats of Recovery Study, respectively. Tables 13 and 14 show group mean clinical chemistry parameters in male and female rats of Main Study, respectively. Tables 15 and 16 show group mean clinical chemistry parameters in male and female rats of Recovery Study, respectively. These data are complementary to the toxicity study of Sepin-1 in Sprague-Dowley rats published previously [1] .
Specifications Table   Subject Toxicology Specific subject area Toxicity profiling of Sepin-1 in Sprague-Dawley Rats Type of data Tables How data were acquired Body and organ weights were collected by using a standard measuring scale. Hematology data were obtained using Siemens Advia 120 Hematology System (Siemens Healthineers, Erlangen, Germany). Clinical chemistry data were collected using Randox Imola Clinical Chemistry Analyzer (Randox Laboratories-US, Ltd, Kearneysville, WV).
Data format Raw, Analysed Experimental factors
Body and organ weights were collected. Hematology and clinical chemistry parameters were obtained from blood samples.
Experimental Features
Body and organ were weighed. Blood samples collected with K 2 EDTA were analyzed for the hematology parameters using Siemens Advia 120 Hematology System. Clotted blood samples were centrifuged, and the serum was used for the clinical chemistry analyses using Randox Imola Clinical Chemistry Analyzer.
Data source location
Baylor College of Medicine Houston, Texas 77030 USA Data accessibility
With the article
Value of the Data
Sepin-1 is a novel inhibitor of Separase and its toxicity is unknown in animals. These data are collected in a GLP setting and useful for Sepin-1 to be further developed in pre-clinical and clinical studies. Researchers in cancer research, pharmacology, toxicology and pharmaceutics will benefit from these data. These data can be used to further study Sepin-1 in haematopoiesis, mechanisms of toxicity, and metabolism.
Experimental design, materials, and methods

Animals
Male and female Sprague-Dawley rats with femoral vein catheters (FVC) (Envigo, Surgical Facility 237, Livermore, CA) were used. The studies were conducted in AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International) accredited BTS Research (San Diego, CA), the contract research organization (CRO). Animals were acclimated to the laboratory environment for a period of 7e8 days. Animals were individually housed in polycarbonate cages containing animal bedding and provided Certified Teklad Rodent Chow 2918 C feed and water at ad libitum. The animals were maintained in environmentally controlled room conditions (18e23 C, 30e70% relative humidity). At the initiation of dosing, rats were 7e9 weeks old with body weights ranging from 180 to 260 g for males and 160e240 g for females. The in-life procedures were performed at BTS Research in accordance with "U.S. 
Dose formulation
Sepin-1 was synthesized by ChemBridge (San Diego, CA). A 40 mg/ml stock solution was prepared by dissolving Sepin-1 in DMSO. Dosing solution for the group receiving 20 mg/kg was prepared by diluting 40 mg/ml stock to 4 mg/ml in 0.01 M citrate-buffed saline (CBS) (0.8%), pH 4.0. The subsequent dosing solutions of 1 and 2 mg/ml were prepared by diluting 4 mg/ml in vehicle control buffer consisting of CBS with 10% dimethyl sulfoxide (CBSD). Dose formulations were prepared daily, and formulations from days 1 and 28 were assessed for drug concentration, homogeneity, and stability by Keystone Bioanalytical (North Wales, PA) using a validated method. All dose solutions were within ±10% of intended concentrations. 
Dosing and Catheter Maintenance
The patency of the FVC was restored every time for dosing. First, exteriorized septum port of FVC was wiped with alcohol wipe or gauze sprayed with 70% alcohol. Then, an appropriate sterile adapter was attached to a 1 ml syringe to access the septum port and withdraw the lock solution until blood is observed. Next, a preloaded syringe was attached, and the preloaded formulated test article was injected at a rate of approximately 2 ml/min. In addition, a preloaded third syringe was attached to inject sterile saline to the flush the line via the adapter (up to 0.4 ml). Finally, a preloaded fourth syringe was attached to inject required amount of lock solution as determined by surgical vendor documentation for FVC indwelling dead volume.
Experimental design
Toxicity Study
A total of 120 Sprague-Dawley rats with indwelling FVCs were randomly assigned to four dose groups (0, 5, 10, or 20 mg/kg/day corresponding to Group 1, 2, 3 and 4, respectively) in the Main Study (40 males and 40 females) and Recovery Study (20 males and 20 females). The animals were dosed via bolus intravenous injection once daily for 28 consecutive days. Animals assigned to the Main Study were euthanized on Day 29 and subjected to histopathological evaluations. The animals in the Recovery Study remained on study for a 28-day off-dose observation period followed by euthanasia and necropsy on Day 29 of the recovery period for histopathological evaluations. Toxicological parameters evaluated were mortality, clinical observations, body weights, food consumption, ophthalmoscopy, clinical pathology (hematology, coagulation, clinical chemistry, and urinalysis), necropsy, organ weights, and histopathology. Unscheduled dead animals were also subjected to necropsy evaluations.
In-life Observations
All animals were observed daily for clinical signs; detailed clinical observations were done once daily during dosing days and once weekly during recovery and prior to necropsy at 4 hours. Individual food consumption was recorded weekly; individual body weights were recorded once during acclimation and at least twice per week during dosing and recovery periods. Ophthalmic evaluations (Direct and Slit-Lamp) of animals in both the Main and Recovery Studies were conducted prior to initiation of treatment and towards the end of the 4th week of the dosing period.
Clinical Pathology
Animals were fasted for at least 8 hours prior to collection of blood for clinical pathology (hematology and clinical chemistry) evaluations at scheduled necropsy on Day 29 (Main Study) and 57 (Recovery Study). Clotted blood samples were centrifuged, and the serum was used for the following clinical chemistry analyses using Randox Imola Clinical Chemistry Analyzer (Randox Laboratories-US, Ltd, Kearneysville, WV): alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, phosphorus, potassium, and sodium. Blood samples collected with K 2 EDTA were analyzed for the following hematology parameters using Siemens Advia 120 Hematology System (Siemens Healthineers, Erlangen, Germany): hemoglobin, hematocrit, platelet counts, leukocyte cell types, and red cell indices (MCV, MCH, and MCHC).
Body and organ weight
Individual body weights were collected from all animals once during acclimation, and at least twice per week for dosing and recovery phase animals. Body weights were collected prior to the withdrawal of food for overnight fasting when fasting and body weights fell on the same day. At the end of study, animals were euthanized via inhalation of isoflurane at 5% followed by exsanguination. Complete necropsy examinations were done for all animals. The organs weighted were brain, adrenal gland, prostate gland, heart, kidney, liver, lung, ovary, spleen, testis, and thymus. Organ weight as a percent of body weight (using the terminal body weight) and organ weight as a percent of brain weight were calculated. 
Statistical evaluation
Data for male and female rats were analyzed separately. All statistics were calculated in Minitab version 16.2.4 by performing an Equal Variance Test with a confidence interval of 95% followed by a One-Way ANOVA with a confidence interval of 95% and a Dunnett comparison test with a family error rate of 5%. Any data that were found to be statistically significant by the Levene's Test P-Value in the Equal Variance Test were normalized by taking the square root of the data and adapting the confidence interval and family error rate for the One-Way ANOVA and Dunnett's comparison test, respectively. 
